Learning From Pixuvri: Pazdur Urges Sponsors To Test Cancer Drugs In Earlier Stages

The Oncologic Drugs Advisory Committee's review of Cell Therapeutics' Pixuvri (pixantrone) - where the treatment for relapsed/refractory non-Hodgkins lymphoma was roundly rejected - was another opportunity for FDA Office of Oncology Drug Products Director Richard Pazdur to urge sponsors to look beyond late-stage settings to test cancer drugs